Browse Category

SWX:ROG.S News 10 January 2026 - 17 January 2026

Roche stock price in focus: Goldman flips to neutral as ROG heads into Jan. 29 results

Roche stock price in focus: Goldman flips to neutral as ROG heads into Jan. 29 results

Zurich, Jan 17, 2026, 17:40 CET — The market has closed. Roche Holding shares (ROG.S) closed Friday 0.93% higher at 348.90 Swiss francs on the Swiss Exchange, a gain of 3.20 francs from Thursday’s finish. Swiss markets remain closed Saturday. (MarketScreener) The shift is significant as broker upgrades begin to reflect a rally that’s driven Roche’s valuation to tighter margins.…
Roche stock in focus after MediLink cancer-drug deal as investors eye Jan. 29 results

Roche stock in focus after MediLink cancer-drug deal as investors eye Jan. 29 results

ZURICH, Jan 10, 2026, 17:45 CET — Market closed Roche Holding (ROG.S) shares edged up on Friday, boosted by news that China’s MediLink Therapeutics secured another licensing deal with the Swiss pharma giant for a cancer drug candidate. Roche participation shares closed 0.4% higher at 340.80 Swiss francs on the SIX Swiss Exchange. (Medilink Therapeutics) Why it matters now: Roche…

Stock Market Today

  • British Biotech IPOs Show Signs of Revival in 2026 After Drought
    January 26, 2026, 1:31 AM EST. British biotech IPOs have been scarce since 2021, with few drug developers going public domestically. The last major listing was Oxford's Exscientia on Nasdaq for $510 million. Despite the U.K. government's efforts, many biotechs still consider U.S. markets like Nasdaq for their public listings, citing deeper capital pools and quality investors. Market signals are shifting-renewed optimism is evident after a strong 2025 for U.S. biotech stocks and positive chatter from major healthcare conferences. Law firms such as Baker McKenzie report growing interest from British biotechs eyeing IPOs, with expectations for at least two new London Stock Exchange listings this year.
Go toTop